Cargando…

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy

Chronic kidney disease is a major complication of Fabry disease. Podocytes accumulate globotriaosylceramide inclusions more than other kidney cell types in Fabry patients. Podocyte injury occurs early in age, and is progressive. Since injured podocytes detach into the urine (podocyturia), we hypothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fall, Brent, Scott, C. Ronald, Mauer, Michael, Shankland, Stuart, Pippin, Jeffrey, Jefferson, Jonathan A., Wallace, Eric, Warnock, David, Najafian, Behzad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161377/ https://www.ncbi.nlm.nih.gov/pubmed/27992580 http://dx.doi.org/10.1371/journal.pone.0168346

Ejemplares similares

Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease
por: Mauer, Michael, et al.
Publicado: (2014)

Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy
por: Braun, Fabian, et al.
Publicado: (2023)

One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease
por: Najafian, Behzad, et al.
Publicado: (2016)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes
por: Trimarchi, Hernán, et al.
Publicado: (2018)

Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease
por: Trimarchi, Hernán, et al.
Publicado: (2017)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy?
por: Waldek, Stephen, et al.
Publicado: (2014)

Current and Investigational Therapeutics for Fabry Disease
por: Felis, Andrew, et al.
Publicado: (2019)

Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease
por: Liebau, Max C., et al.
Publicado: (2013)

Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy
por: Levstek, Tina, et al.
Publicado: (2021)

Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine: A case report
por: Kanai, Takahiro, et al.
Publicado: (2022)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

The coincidence of IgA nephropathy and Fabry disease
por: Maixnerová, Dita, et al.
Publicado: (2013)

Biomarkers of Fabry Nephropathy: Review and Future Perspective
por: Levstek, Tina, et al.
Publicado: (2020)

Treatment of Fabry Nephropathy: A Literature Review
por: Shimohata, Homare, et al.
Publicado: (2023)

Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
por: Kim, Il Young, et al.
Publicado: (2021)

Direct Correlation between Age at Diagnosis and Severity of Nephropathy in Fabry Disease Patients
por: Jaurretche, Sebastián P. A., et al.
Publicado: (2019)

Diagnosing Fabry nephropathy: the challenge of multiple kidney disease
por: Esposito, Pasquale, et al.
Publicado: (2023)

Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
por: Prabakaran, Thaneas, et al.
Publicado: (2011)

Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Hearing loss in children with Fabry disease
por: Suntjens, E., et al.
Publicado: (2017)

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
por: Schiffmann, Raphael, et al.
Publicado: (2009)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Parietal epithelial cell differentiation to a podocyte fate in the aged mouse kidney
por: Kaverina, Natalya V., et al.
Publicado: (2020)

Pathologic findings of Fabry nephropathy: the pivotal role of kidney biopsy
por: Shin, Jung-ho, et al.
Publicado: (2021)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation
por: Zhang, Jiong, et al.
Publicado: (2014)

Divergent Impact of Enzyme Replacement Therapy on Human Cardiomyocytes and Enterocytes Affected by Fabry Disease: Correlation with Mannose-6-phosphate Receptor Expression
por: Frustaci, Andrea, et al.
Publicado: (2022)

Coincidental finding of Fabry’s disease in a patient with IgA nephropathy
por: Kakita, Tomoko, et al.
Publicado: (2010)

Is there a pathogenic association between Fabry’s disease and IgA nephropathy?
por: Fujinaga, Shuichiro, et al.
Publicado: (2013)

Coexistence of Fabry disease with IgM nephropathy: A case report
por: Wu, Huizhen, et al.
Publicado: (2019)

A questionnaire survey on the diagnosis and treatment of Fabry nephropathy in clinical practice
por: Choi, Soo Jeong, et al.
Publicado: (2023)

Concurrent fabry disease and immunoglobulin a nephropathy: a case report
por: Zhou, Li-Na, et al.
Publicado: (2023)

Late onset variants in Fabry disease: Results in high risk population screenings in Argentina
por: Serebrinsky, G., et al.
Publicado: (2015)

Fabry Nephropathy in a Young Female Patient Presenting with Only Urinary Mulberry Bodies Treated with Chaperone Therapy
por: Fukunaga, Tsugumi, et al.
Publicado: (2021)

The phenotypes of podocytes and parietal epithelial cells may overlap in diabetic nephropathy
por: Andeen, Nicole K., et al.
Publicado: (2015)

Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis
por: Eng, Diana G., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3bgifl8rg2dqfi0o43ahkqcjbo